研究单位：[1]Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology,Wuhan,Hu Bei Province,China[2]No.1 Peoples Hospital of Guangshui,Guangshui,Hu Bei Province,China[3]Huanggang Central Hospital,Huanggang,Hu Bei Province,China[4]People's Hospital of Luotian County,Huanggang,Hu Bei Province,China[5]People's Hospital of Macheng City, Affiliated Hospital of Hubei University of Science and Technology,Macheng,Hu Bei Province,China[6]Qianjiang Central Hospital,Qianjiang,Hu Bei Province,China[7]Xianning Central Hospital,Xianning,Hu Bei Province,China[8]The Third Peoples Hospital of Yichang,Yichang,Hu Bei Province,China[9]Jiangsu Province Hospital,Nanjing,Jiangsu,China
The goal of this randomized study to test the efficacy of different doses of IVIG (intravenous immunoglobulin) in the treatment of severe HFRS（hemorrhagic fever with renal syndrome）, and provide new clinical ideas for the treatment and prognosis of HFRS patients in the future. This study will include all hospitalized patients with confirmed severe or critically ill HFRS from October 2021 to October 2023 from 9 centers. Participants will receive IVIG 10g/d or IVIG 20g/d. All the participants will be given conventional liquid therapy and symptomatic and supportive treatment. Participants will be collected demographic, epidemiological history, hospitalization information, clinical data, laboratory data, imaging results, treatment regimens, and outcomes data.
